Browsing Tag

Test Utilization

General Information, Test Utilization

New PSA Screening Order Validation Rules

What’s Changing?

Beginning March 9, 2026, a new Order Validation Rules in Epic will apply to all PSA Screening orders. These rules act as hard stops and must be corrected before the order can be signed.

Applies to:

• Prostate Specific Antigen (PSA), Screening [LAB116]

Epic will stop the order if:

Diagnosis Code Is Not Z12.5. Z12.5 (Screening for Prostate Cancer) is required for all PSA Screening orders.

Patient Is <40 Years Old With BCBS Coverage. BCBS does not cover PSA Screening for this group.

Patient Is <50 Years Old With Medicare / Medicare Advantage. Medicare does not deem PSA Screening medically necessary before age 50.

Screening Was Performed Within the Past 11 Months. Annual screening limits apply; users must change the expected date if needed.


Important for Providers Ordering Outside Epic

External practices will not see Epic’s validation warnings, but the draw site (phlebotomy team) will.

What Happens at the Draw Site?

If a paper/EMR PSA Screening order violates any rule:

1. Phlebotomy attempts to enter the order.
2. A hard stop fires in Epic.
3. The phlebotomist cannot override the alert.
4. The order cannot be placed, even with a signed requisition.
5. Staff will:

Inform the patient
Contact the ordering provider for correction
Hold the draw until the provider updates the order

This may require the patient to return if changes can’t be made immediately.

How Providers Can Prevent Delays

✔ Use Z12.5 for all PSA Screening orders
✔ Confirm age + insurance coverage requirements
✔ Ensure no PSA Screening has occurred in the past 11 months
✔ Order a diagnostic PSA instead of a screening when appropriate (symptoms, abnormal findings, ongoing monitoring)

 

 

Referral/Sendouts, Southeast Michigan, Southwest Michigan, West Michigan

Primary Reference Lab Change to Quest Diagnostics

Effective November 19, 2025

Corewell Health Laboratory is transitioning to Quest Diagnostics as our primary reference testing laboratory. This change means that nearly all referral and send-out tests will now be performed by Quest Diagnostics. A limited number of tests will continue to be sent to other laboratories to ensure we meet the needs of our patients and clinicians.

What You Need to Know:

  • Test Crosswalks: Tests currently performed at ARUP and Mayo Clinic Labs will be matched to comparable tests at Quest Diagnostics.
  • Discontinued Tests: Tests with low utilization or those no longer deemed clinically necessary will be discontinued.
  • New LAB Numbers: All tests will receive new LAB numbers, which must be updated in your EMR compendium if interfaced.
  • Collection Devices: Some tests may require different collection devices.
  • Transition Timeline:
    • November 19, 2025: Focus on tests currently referred to ARUP.
    • December 17, 2025: Focus on tests currently referred to Mayo Clinic Labs.
  • Crosswalk Resources: Crosswalks between current and future test offerings will be provided to help you prepare.
  • Test Directory Access: Please refer to your regional Lab Test Directory for details on specific test changes. ARUP and Mayo Clinic Lab test pages will include links to the corresponding Quest Diagnostic tests.

We understand the significance of these changes and are committed to supporting your practice throughout this transition. Updates and modifications will be communicated promptly.

Contact Information:

  • Corewell Health East Sendouts: 248.551.9045
  • Corewell Health West Referrals: 616.267.2753
  • Or use the Contact Us link above.
Emergency, Inpatient, Test Utilization, West Michigan

Hypercoagulation/Thrombophilia Tests No Longer Available for Adult Emergency Room (ED) and Inpatient

Effective 10/29/2025, hypercoagulation/thrombophilia test ordering will no longer be available in the adult inpatient and emergency department settings at Corewell Health West.

This change aligns the hospital system with the American Society of Hematology Choosing Wisely initiative. This will decrease unnecessary costly testing in the inpatient setting and help to prevent inappropriate diagnoses. Continue Reading

General Information

Test Update: PD-L1

Effective July 30, 2025, PD-L1 testing will be performed at Corewell Health Reference Laboratory East and will no longer be a sendout to Neogenomics. Collection instructions and other information may have changed, please visit the lab catalog for more information.

For questions and inquiries, please use the “Contact Us” link above.

 

TEST INFORMATION

New test: PD-L1 [LAB3658]

Former test: PD-L1 to Neogenomics (LAB848)

Advanced Technology Laboratory, Cytology, General Information

Reflex HPV Testing Update

Effective April 2, 2025, the Reflex HPV algorithm will more closely align with ASCCP recommendations. HPV testing will no longer be performed for a normal Pap result in patients aged 30 years and older when a provider orders HPV Reflex.

Specimens will qualify for HPV Reflex with a cytologic diagnosis of:

  • ASCUS (Atypical Squamous Cells of Undetermined Significance) for patients aged 21 and older.
  • LSIL (Low Grade Squamous Intraepithelial Lesion) for patients aged 25 and older.

HPV testing will continue to be performed for all Paps, regardless of results, for patients aged 30 years or older when a provider orders Co-Testing.

If a provider wishes to request HPV testing on a normal pap for patients under 30, they must either place an electronic order at the time of the initial pap order or request an add-on test for:

  • HPV High Risk Screen with HPV Genotype Reflex – Cervical Source (LAB1231770)
  • HPV High Risk Screen with HPV Genotype Reflex – Vaginal Source (LAB1230721)

Updated Pap and HPV Testing Algorithm

Continue Reading

Compliance & Safety

Anti-TPO Assay Falsely Elevated Recovery

A reagent bulletin from Roche has informed us that the recovery of the Anti-TPO assay has been falsely elevated for a reagent lot that was in use at Corewell Health Grand Rapids from September 2024 until March, 3, 2025. Based on the product evaluation, and in conjunction with a product and safety risk assessment, the remaining risk of false positive results with the Elecsys Anti-TPO assay is in the acceptable range.

We apologize for the inconvenience. Please reach out with any concerns or questions.

Best,

Dr. Alvarez
Yasel Alvarez, Ph.D.
Clinical Chemistry and Immunology
Corewell Health Reference Laboratory, West Michigan

Test Information

Thyroid Peroxidase Antibody, Blood Level [LAB516]

Clinical Implications

The risk of false positive results with the Elecsys anti-TPO assay is generally acceptable with respect to the given discrepancy.

Resources

Roche Customer Bulletin TP-02316

Education & Training, General Information, Test Utilization

Thyroid Disease Awareness Month

Written by Yasel Fleitas Alvarez, Ph.D., Chemistry Clinical Advisor, Corewell Health Reference Laboratory West, Michigan Pathology Specialists.

This January we are celebrating the National Thyroid Awareness Month. In United States of America, it is estimated that approximately 20 million people have thyroid disease and most importantly, according to the American Thyroid Association (ATA) as many as 60% of people suffering from a thyroid disorder are not aware they have it.The thyroid is a butterfly shaped-gland located at the front of the neck that produces and release thyroid hormones (See Figure 1).

Figure 1. Thyroid Gland Anatomy and Histology

 

It regulates important physiological functions as:

    • Breathing
    • Heart rate
    • Energy production
    • Muscle strength
    • Body temperature
    • Weight
    • Mood

Thyroid disease can present in two main forms:

  1. Hypothyroidism (under functioning thyroid)
  2. Hyperthyroidism (over functioning thyroid)

Confirmation or exclusion of thyroid disease requires a clinical examination combined with biochemical determination of thyroid hormones (TH) and thyrotropin (TSH)concentrations.

In this blog we discuss the best practices for ordering thyroid function tests for the initial screening of thyroid disease at Corewell Health.
Continue Reading

Advanced Technology Laboratory, Compliance & Safety, General Information

Genetic Testing Informed Consent

Submission of an order for any predictive genetic tests and pre-symptomatic genetic tests, as defined by MCL 333.17020, contained in Corewell Health laboratory catalog constitutes certification to Corewell Health Laboratories that the ordering physician understands that written, informed consent is required for these tests and that, by submitting an order for these genetic tests, ordering physician has obtained “Informed Consent” of subject patient as required by any applicable state or federal laws with respect to each test ordered. On occasion, we forward a specimen to an outside reference laboratory. Corewell Health laboratories may request that ordering physician provide such consent to Corewell Health upon a reasonable request.

Continue Reading

Microbiology

Test Update: Influenza Rapid and RSV Rapid Tests Discontinued

Effective October 3, 2023, Corewell Health Laboratories will discontinue the Influenza Rapid and Respiratory Syncytial Virus (RSV) Rapid tests. These antigen tests are less sensitive than the nucleic acid amplification tests (NAAT; such as PCR) that are now the standard of care for diagnosing these respiratory viruses. Specimen collection remains unchanged with PCR testing available for nasopharyngeal and nasal swabs collected in a universal transport media (UTM) tube.

Discontinued:

• Influenza (Flu) A/B Rapid – Epic Code: LAB9240
• Influenza (Flu) A/B Rapid, Influenza A/B PCR if Negative – Epic Code: LAB2111530
• Respiratory Syncytial Virus (RSV) Rapid – Epic Code: LAB495

Replace with:

• Influenza (Flu) A/B PCR – Epic Code: LAB3255
• COVID-19, Influenza A/B, RSV PCR – Epic Code: LAB1230746